LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email pr@fool.com Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Simulations Plus faces soft revenue growth in the short term, due largely to macro conditions. The negatives appear to have been priced in, though, after a period of significant share price declines.

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O ...

Simulations Plus is a software company that develops tools for modeling and simulation in the pharmaceutical, biotechnology, and chemical industries. In June 2024, Simulations Plus acquired ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

Earnings call Simulations Plus reported Q2 FY25 revenue of $22.4M, up 23% YoY, with 5% organic growth. Software revenue rose 16% and services 34%, though services were flat organically. Management ...

NEW YORK CITY, NY / ACCESS Newswire / August 29, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ:SLP) for potential ...

Polen Capital Management, a value-driven, concentrated, long-term investment management firm, published its ‘Polen U.S. Small Company Growth’ fourth-quarter 2020 Investor Letter – a copy of which can ...